Moreover, unlike AFP, measuring SNHG1 levels appears to improve the prediction of prognosis for HCC patients, providing clinicians with better insights regarding the aggressiveness of the tumor, the survival likelihood, and the selection of appropriate therapies from the outset. This evidence concerns the gene AFP and neoplasm.